In India, a second COVID-19 vaccination for children and adolescents has been approved for emergency use. Corbevax from Biological E Ltd has received EUA for adolescents aged 12 to 18, according to a statement released today.
Since January 3, India has begun providing Bharat Biotech’s Covaxin to teenagers aged 15 to 18.
The EUA, or emergency use authorization, for Corbevax’s restricted usage in emergencies among adults, was approved by India’s drug regulator, the Drugs Controller General, in December 2019.
BE got permission for restricted use in an emergency circumstance in teenagers aged 12 to 18 years based on intermediate results (of the current phase II/III clinical research), according to a statement released today by Biological E.
Corbevax is being marketed as India’s first “receptor-binding domain protein subunit vaccination against COVID-19.” A receptor-binding domain is a critical component of a virus that is positioned on its “spike” domain and helps it to attach to body receptors in order to enter and infect cells. These are also the key objectives for viral infection prevention and therapy.
Mahima Datla, Managing Director of Biological E, stated in a statement that they are happy with this big milestone, which helps broaden the reach of their vaccination in the country to the age bracket of 12 to 18 years. They stated that they are certain that with this certification, they are one step closer to completing the global fight against the COVID-19 pandemic.
Biological E received approval in September to undertake phase II and III clinical studies on Corbevax in children and adolescents aged 5 to 18 years.
Corbevax is injected intramuscularly in two doses 28 days apart and is kept at 2 to 8 degrees Celsius. According to BE, it is available in 0.5 mL (single dosage), 5 mL (10 doses), and 10 mL (20 doses) vial packs.